Update date
30 Jun 2024
Shareable Research Card
BIOX - Bioceres Crop Solutions Corp. Research And Development Expense
This metric view shows BIOX - Bioceres Crop Solutions Corp. research and development expense history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: Q2 2024
- Latest reported value
- $5,368,622
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 30 Jun 2024
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: Q2 2024.
- Latest reported value on this page: $5,368,622.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest update for Research And Development Expense
Latest reported research and development expense: $5,368,622. Open the source-backed page to compare this metric with the newest filing-backed context.
Page type
Metric history
Latest period
Q2 2024
SEC-backed company facts were refreshed from filings filed on 30 Oct 2024.
Benchmark Context
How Research And Development Expense compares with peers
Bioceres Crop Solutions Corp. sits in the bottom quarter of the current research and development expense sample.
Compared with
Compared with 120 companies reporting research and development expense in USD. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 0.2x the current sample midpoint. Research And Development Expense is up about 30% versus the comparable prior period.
- Visible rows currently span reported period ends from 31 Dec 2017 to 31 Dec 2025.
- Nearby companies in this sample: Pulsenmore Ltd. and SHL TELEMEDICINE LTD.
- Current sample position: rank #113 of 120 comparable companies.
- Peer rows use the latest valid value per company for this exact metric and compatible units.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists and return after a new SEC filing changes the record here.
Financial Metric Page
Bioceres Crop Solutions Corp.: Research And Development Expense
Latest period: Q2 2024. Period end: 30 Jun 2024. Units: USD. Frequency: quarterly and annual.
Research And Development Expense is an SEC-reported metric from company XBRL facts.
Metric Snapshot
- Latest value
- $5,368,622
- Coverage range
- 31 Dec 2016 - 30 Jun 2024
- Fact rows
- 21
What This Metric Tells You
- Shows the reported level of research and development expense over 31 Dec 2016 - 30 Jun 2024.
- Includes year-over-year change points to highlight acceleration or slowdown.
- Built from 21 SEC fact rows for this metric and issuer.
How To Read This Chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use quarterly sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
- Use the TTM line to smooth quarter-to-quarter noise.
Official SEC Source
Source: SEC Company Facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
Direct filing link is shown only when a matched SEC filing document is available for this metric context.
Compare This Metric Across Companies
Compare latest available Research And Development Expense levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
Bioceres Crop Solutions Corp. appears at rank #113 in the latest comparison sample.
| Rank | Company | Latest value | Reported period | Next step |
|---|---|---|---|---|
| 1 | ASTRAZENECA PLC (azn) | $14,232,000,000 | Year - 31 Dec 2025 | Open ASTRAZENECA PLC Research And Development Expense |
| 2 | NOVARTIS AG (nvs) | $11,200,000,000 | Year - 31 Dec 2025 | Open NOVARTIS AG Research And Development Expense |
| 3 | TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD (tsm) | $6,227,000,000 | Year - 31 Dec 2024 | Open TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD Research And Development Expense |
| 4 | SAP SE (sap) | $4,030,000,000 | Year - 31 Dec 2017 | Open SAP SE Research And Development Expense |
| 5 | GENMAB A/S (gmab) | $1,606,000,000 | Year - 31 Dec 2025 | Open GENMAB A/S Research And Development Expense |
| 6 | Atlassian Corp (team) | $1,397,568,000 | Year - 30 Jun 2022 | Open Atlassian Corp Research And Development Expense |
Metric Details
- Metric
- Research And Development Expense (ResearchAndDevelopmentExpense)
- Taxonomy
- ifrs-full
- Units tracked
- USD
- Frequency coverage
- quarterly and annual
- History range
- 31 Dec 2016 - 30 Jun 2024
- Facts on this page
- 21
- Metric-level SEC endpoint
- Open SEC company concept
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Research And Development Expense, Trailing 12 Months (USD)
Research And Development Expense, Quarterly (USD)
Research And Development Expense, YoY Quarterly Change (%)
Research And Development Expense, Annual (USD)
Research And Development Expense, YoY Annual Change (%)
Bioceres Crop Solutions Corp. Quarterly Research And Development Expense (USD)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2024 | $17,183,041 | $5,368,622 | +$1,227,100 | +30% | 01 Apr 2024 | 30 Jun 2024 | 20-F | 30 Oct 2024 | 2024 | FY |
| Q1 2024 | $15,955,941 | $3,590,101 | -$303,786 | -7.8% | 01 Jan 2024 | 31 Mar 2024 | 6-K | 29 May 2024 | 2024 | Q3 |
| Q4 2023 | $16,259,727 | $3,643,077 | +$185,185 | +5.4% | 01 Oct 2023 | 31 Dec 2023 | 6-K | 28 Feb 2024 | 2024 | Q2 |
| Q3 2023 | $16,074,542 | $4,581,241 | +$729,227 | +19% | 01 Jul 2023 | 30 Sep 2023 | 6-K | 29 Nov 2023 | 2024 | Q1 |
| Q2 2023 | $15,345,315 | $4,141,522 | 01 Apr 2023 | 30 Jun 2023 | 20-F | 30 Oct 2024 | 2024 | FY | ||
| Q1 2023 | $3,893,887 | +$2,057,858 | +112% | 01 Jan 2023 | 31 Mar 2023 | 6-K | 29 May 2024 | 2024 | Q3 | |
| Q4 2022 | $3,457,892 | +$2,073,860 | +150% | 01 Oct 2022 | 31 Dec 2022 | 6-K | 28 Feb 2024 | 2024 | Q2 | |
| Q3 2022 | $3,852,014 | 01 Jul 2022 | 30 Sep 2022 | 6-K | 29 Nov 2023 | 2024 | Q1 | |||
| Q1 2022 | $1,836,029 | 01 Jan 2022 | 31 Mar 2022 | 6-K | 24 May 2023 | 2023 | Q3 | |||
| Q4 2021 | $1,384,032 | +$269,212 | +24% | 01 Oct 2021 | 31 Dec 2021 | 6-K | 28 Feb 2023 | 2023 | Q2 | |
| Q4 2020 | $1,114,820 | +$191,207 | +21% | 01 Oct 2020 | 31 Dec 2020 | 6-K | 25 Feb 2022 | 2022 | Q2 | |
| Q4 2019 | $923,613 | +$877,948 | +1923% | 01 Oct 2019 | 31 Dec 2019 | 6-K | 26 Feb 2021 | 2021 | Q2 | |
| Q4 2018 | $45,665 | 01 Oct 2018 | 31 Dec 2018 | 6-K/A | 17 Mar 2020 | 2019 | Q2 |
Bioceres Crop Solutions Corp. Annual Research And Development Expense (USD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2024 | $17,183,041 | +$1,837,726 | +12% | 01 Jul 2023 | 30 Jun 2024 | 20-F | 30 Oct 2024 | 2024 | FY |
| 2023 | $15,345,315 | +$8,397,855 | +121% | 01 Jul 2022 | 30 Jun 2023 | 20-F | 30 Oct 2024 | 2024 | FY |
| 2022 | $6,947,460 | +$1,329,805 | +24% | 01 Jul 2021 | 30 Jun 2022 | 20-F | 30 Oct 2024 | 2024 | FY |
| 2021 | $5,617,655 | +$1,422,385 | +34% | 01 Jul 2020 | 30 Jun 2021 | 20-F | 14 Nov 2023 | 2023 | FY |
| 2020 | $4,195,270 | +$505,879 | +14% | 01 Jul 2019 | 30 Jun 2020 | 20-F | 28 Oct 2022 | 2022 | FY |
| 2019 | $3,689,391 | -$260,709 | -6.6% | 01 Jul 2018 | 30 Jun 2019 | 20-F | 29 Oct 2021 | 2021 | FY |
| 2018 | $3,950,100 | 01 Jul 2017 | 30 Jun 2018 | 20-F | 21 Oct 2020 | 2020 | FY | ||
| 2016 | $853,854 | 01 Jan 2016 | 31 Dec 2016 | 20-F | 24 Oct 2019 | 2019 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.